Stock Events

Stock Events

Pharvaris NV

€24.9

0

+€0.85+3.53% Thursday 06:03

Statistics

Day High

24.9

Day Low

24.9

52W High

25.05

52W Low

13.7

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

13MayExpected

Next

-0.71

-0.37

-0.04

0.29

Expected EPS

-0.7054547619585855

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 9EN.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes innovative therapies for patients with serious and life-threatening rare diseases and medical conditions, including genetic disorders, which is a similar focus area to Pharvaris' work on hereditary angioedema.

Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited operates in various therapeutic areas, including rare diseases, which aligns with Pharvaris' focus on providing treatments for rare conditions like hereditary angioedema.

Carlisle Companies

CSL Behring is a global biotherapies leader which develops and delivers innovative therapies for people with rare and serious diseases, competing directly in the space of treatments for conditions like those Pharvaris targets.

Vertex Pharmaceuticals

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is a leader in RNAi therapeutics for the treatment of rare genetic diseases, which competes with Pharvaris' approach to targeting genetic disorders.

Biogen Inc. focuses on developing therapies for neurological and neurodegenerative diseases, along with rare diseases, positioning it as a competitor in the rare disease sector.

Sarepta Therapeutics

Sarepta Therapeutics, Inc. is focused on the discovery and development of RNA-based therapeutics for the treatment of rare diseases, directly competing with Pharvaris' focus areas.

Amgen Inc. is a global biotechnology company that develops and produces innovative human therapeutics, including treatments for rare diseases, making it a competitor in the rare disease therapeutic market.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is known for its development of treatments for serious medical conditions, including rare diseases, which places it in direct competition with Pharvaris in the rare disease market.

About

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Show more...

CEO

ISIN

NL00150005Y4

Listings

0 Comments

Share your thoughts

FAQ

What is Pharvaris NV stock price today?▼

The current price of 9EN.MU is €24.9 EUR — it has increased by +3.53% in the past 24 hours. Watch Pharvaris NV stock price performance more closely on the chart.

What is Pharvaris NV stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Pharvaris NV stocks are traded under the ticker 9EN.MU.

Is Pharvaris NV stock price growing?▼

9EN.MU stock has risen by +3.53% compared to the previous week, the month change is a +0.4% rise, over the last year Pharvaris NV has showed a +53.7% increase.

When is the next Pharvaris NV earnings date?▼

Pharvaris NV is going to release the next earnings report on May 13, 2026.

In which sector is Pharvaris NV located?▼

Pharvaris NV operates in the Other sector.

When did Pharvaris NV complete a stock split?▼

Pharvaris NV has not had any recent stock splits.